Eva Galante

Eva Galante

Auto-generated profile, based on publicly available information

Eva Galante

University College London

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RYRan Yan
Ran Yan
KSKerstin Sander
Kerstin Sander
EGEva Galante
Eva Galante
VRVineeth Rajkumar
Vineeth Rajkumar
ABAdam Badar
Adam Badar
EAErik Arstad
Erik Arstad

23 February 2008 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
Corrada GeraciCorrada Geraci
Corrada Geraci
GCGrazia M. L. Consoli
Grazia M. L. Consoli
EGEva Galante
Eva Galante
EBEnnio Bousquet
Ennio Bousquet
MPMaria Pappalardo
Maria Pappalardo
ASAngelo Spadaro
Angelo Spadaro

16 September 2013 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
Corrada GeraciCorrada Geraci
Corrada Geraci
GCGrazia M. L. Consoli
Grazia M. L. Consoli
GGGiuseppe Granata
Giuseppe Granata
EGEva Galante
Eva Galante
APAngelo Palmigiano
Angelo Palmigiano
ASAngelo Spadaro
Angelo Spadaro

8 January 2015 in Human Gene Therapy
Verified
Journal Article
Closed access
MPMarco Della Peruta
Marco Della Peruta
ABAdam Badar
Adam Badar
CRCecilia Rosales
Cecilia Rosales
SCShilpa Chokshi
Shilpa Chokshi
AKAzadeh Kia
Azadeh Kia
ANAmit C. Nathwani
Amit C. Nathwani
A novel selectively targeting gene delivery approach has been developed for advanced hepatocellular carcinoma (HCC), a leading cause of cancer mortality whose prognosis remains poor. We combine the strong liver tropism of serotype-8 capsid-pseudotyped adeno-associated viral vectors (AAV8) with a liver-specific promoter (HLP) and microRNA-122a ( miR-122a )-mediated posttranscriptional regulation. Systemic administration of our AAV8 construct resulted in preferential transduction of the liver and encouragingly of HCC at heterotopic sites, a finding that could be exploited to target disseminated disease. Tumor selectivity was enhanced by inclusion of miR-122a -binding sequences (ssAAV8-HLP-TK-122aT4) in the expression cassette, resulting in abrogation of transgene expression in normal murine liver but not in HCC. Systemic administration of our tumor-selective vector encoding herpes simplex virus-thymidine kinase ( TK ) suicide gene resulted in a sevenfold reduction in HCC growth in a syngeneic murine model without toxicity. In summary, we have developed a systemically deliverable gene transfer approach that enables high-level expression of therapeutic genes in HCC but not normal tissues, thus improving the prospects of safe and effective treatment for advanced HCC.

1 August 2011 in Tetrahedron
Verified
Journal Article
Closed access
EGEva Galante
Eva Galante
CGCorrada Geraci
Corrada Geraci
SSSebastiano Sciuto
Sebastiano Sciuto
VCVanessa L. Campo
Vanessa L. Campo
ICIvone Carvalho
Ivone Carvalho
RFRobert A. Field
Robert A. Field

1 September 2006 in Tetrahedron Letters
Verified
Journal Article
Closed access
GCGrazia M.L. Consoli
Grazia M.L. Consoli
EGEva Galante
Eva Galante
CDCarmelo Daquino
Carmelo Daquino
GGGiuseppe Granata
Giuseppe Granata
FCFrancesca Cunsolo
Francesca Cunsolo
CGCorrada Geraci
Corrada Geraci